The Interleukin-8 (IL-8/CXCL8) Receptor Inhibitor Reparixin Improves Neurological Deficits and Reduces Long-term Inflammation in Permanent and Transient Cerebral Ischemia in Rats

Leukocyte infiltration is viewed as a pharmacological target in cerebral ischemia. We previously reported that reparixin, a CXCL8 receptor blocker that inhibits neutrophil infiltration, and related molecules can reduce infarct size in a rat model of transient middle cerebral artery occlusion (MCAO). The study aims were to compare the effects of reparixin in transient and permanent MCAO using varied treatment schedules and therapeutic windows to evaluate effects on long-term neurological deficits and late inflammatory response. Reparixin, administered for 1 to 3 days, 3.5 to 6 h after MCAO, ameliorates neurological function recovery and inhibits long-term inflammation. The infarct size reduction at 24 h, evaluated by TTC staining, is more pronounced in transient MCAO. MRI analysis identified a decrease in the progression of infarct size by reparixin that was more evident at 48 h in permanent MCAO, and was associated with a significantly improved recovery from long-term neurological deficits.

[1]  P. Ghezzi,et al.  Reduced Functional Deficits, Neuroinflammation, and Secondary Tissue Damage after Treatment of Stroke by Nonerythropoietic Erythropoietin Derivatives , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  G. Reiser,et al.  Protease‐activated receptor‐1 protects rat astrocytes from apoptotic cell death via JNK‐mediated release of the chemokine GRO/CINC‐1 , 2006, Journal of neurochemistry.

[3]  R. Pedotti,et al.  Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis , 2006, Journal of Neuroimmunology.

[4]  J. Bolz,et al.  Neurogenesis in the adult dentate gyrus after cortical infarcts: Effects of infarct location, N-methyl-d-aspartate receptor blockade and anti-inflammatory treatment , 2005, Neuroscience.

[5]  T. Palmer,et al.  Neurogenesis in Rats After Focal Cerebral Ischemia is Enhanced by Indomethacin , 2005, Stroke.

[6]  Douglas C. Miller,et al.  Minimally invasive method for murine brain fixation. , 2005, BioTechniques.

[7]  N. Rothwell,et al.  A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  F. Colotta,et al.  Neutrophil Recruitment in the Reperfused-Injured Rat Liver was Effectively Attenuated by Repertaxin, a Novel Allosteric Noncompetitive Inhibitor of Cxcl8 Receptors: A Therapeutic Approach for the Treatment of Post-Ischemic Hepatic Syndromes , 2005, International journal of immunopathology and pharmacology.

[9]  P. Ghezzi,et al.  Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia. , 2005, Cytokine.

[10]  R. Busto,et al.  Neuroprotective Effect of Darbepoetin Alfa, a Novel Recombinant Erythropoietic Protein, in Focal Cerebral Ischemia in Rats , 2005, Stroke.

[11]  K. Abe,et al.  Cannabidiol Prevents Cerebral Infarction Via a Serotonergic 5-Hydroxytryptamine1A Receptor–Dependent Mechanism , 2005, Stroke.

[12]  David C. Hess,et al.  Targets for Vascular Protection After Acute Ischemic Stroke , 2004, Stroke.

[13]  Pietro Ghezzi,et al.  Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  David W Howells,et al.  Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias , 2004, Stroke.

[15]  Hiroki Toda,et al.  Inflammatory Blockade Restores Adult Hippocampal Neurogenesis , 2003, Science.

[16]  O. Lindvall,et al.  Inflammation is detrimental for neurogenesis in adult brain , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Plotkine,et al.  Polymorphonuclear neutrophils contribute to infarction and oxidative stress in the cortex but not in the striatum after ischemia–reperfusion in rats , 2003, Brain Research.

[18]  N. Rothwell,et al.  Delayed administration of interleukin‐1 receptor antagonist protects against transient cerebral ischaemia in the rat , 2003, British journal of pharmacology.

[19]  E. Tremoli,et al.  Treatment With Statins After Induction of Focal Ischemia in Rats Reduces the Extent of Brain Damage , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[20]  P. Lewczuk,et al.  Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial , 2002, Molecular medicine.

[21]  B. Pollo,et al.  New Insights Into Brain Damage in Stroke-Prone Rats: A Nuclear Magnetic Imaging Study , 2002, Stroke.

[22]  R. Bartus,et al.  The Role of Leukocytes Following Cerebral Ischemia: Pathogenic Variable or Bystander Reaction to Emerging Infarct? , 2002, Experimental Neurology.

[23]  Steven C. R. Williams,et al.  Neuroprotection in Ischemia–Reperfusion Injury: An Antiinflammatory Approach Using a Novel Broad-Spectrum Chemokine Inhibitor , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[24]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Reglodi,et al.  Postischemic Spontaneous Hyperthermia and Its Effects in Middle Cerebral Artery Occlusion in the Rat , 2000, Experimental Neurology.

[26]  P. Kivisäkk,et al.  Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. , 1999, Stroke.

[27]  F. Barone,et al.  Inflammatory Mediators and Stroke: New Opportunities for Novel Therapeutics , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  M. Schwartz,et al.  Innate and adaptive immune responses can be beneficial for CNS repair , 1999, Trends in Neurosciences.

[29]  W. Koroshetz,et al.  Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. The RANTTAS Investigators. , 1999, Stroke.

[30]  S. Ekholm,et al.  Intrathecal release of pro‐ and anti‐inflammatory cytokines during stroke , 1997, Clinical and experimental immunology.

[31]  K. Tracey,et al.  Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Y. Itoyama,et al.  Transient increase of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, in ischemic brain areas after focal ischemia in rats. , 1995, Stroke.

[33]  H. Sarau,et al.  Reperfusion Increases Neutrophils and Leukotriene B4 Receptor Binding in Rat Focal Ischemia , 1992, Stroke.

[34]  M. Borgers,et al.  Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. , 1989, Stroke.

[35]  Timothy Schallert,et al.  Seizures and recovery from experimental brain damage , 1988, Experimental Neurology.

[36]  L. Pitts,et al.  Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. , 1986, Stroke.

[37]  M. Nishimura,et al.  Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. , 1986, Stroke.

[38]  W. Moloney,et al.  ESTERASE ACTIVITY IN LEUKOCYTES DEMONSTRATED BY THE USE OF NAPHTHOL AS-D CHLOROACETATE SUBSTRATE , 1960, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[39]  B. Siesjö,et al.  Ischemic penumbra in a model of reversible middle cerebral artery occlusion in the rat , 2004, Experimental Brain Research.

[40]  R. Ransohoff,et al.  Chemokines and chemokine receptors in CNS pathology. , 1999, Journal of neurovirology.